Table 1. Antiproliferative potencies of NRs, ATRA, 4-HPR, and FDA approved PCa drugs in androgen sensitive and castration resistant human prostate cancer cell lines.
| Compound | PWR-1E (μM) | PC-3 (μM) | C4-2B (μM) | 22Rv1 (μM) | LNCaP (μM) | LNCaP (μM, DHT induced) |
|---|---|---|---|---|---|---|
| VN/14-1 | 69.18 | 36.3 | 9.76 | 12.88 | 11.32 | 12.88 |
| VN/66-1 | 19.05 | 10.71 | 2.38 | 2.95 | 4.67 | 1.54 |
| VNLG-145 | 25.11 | 4.26 | 2.14 | 2.23 | 2.45 | 2.23 |
| VNLG-146 | 63.09 | 57.54 | 11.74 | 39.81 | 57.54 | 52.48 |
| VNLG-147 | 71.53 | 2.95 | 2.66 | 2.04 | 1.86 | 1.41 |
| VNLG-148 | 43.65 | 36.3 | 15.48 | 39.81 | 22.9 | 19.05 |
| VNLG-152 | 47.86 | 5.62 | 1.54 | 3.23 | 2.45 | 1.86 |
| VNLG-153 | 39.81 | 4.36 | 2.97 | 2.23 | 3.23 | 2.69 |
| ATRA | 75.3 | 36.3 | 11.74 | 25.11 | 47.86 | 39.81 |
| 4-HPR | 1.07 | 3.54 | 3.11 | 3.23 | 2.69 | 2.45 |
| Casodex | 69.1 | 9.15 | 1.51 | 3.81 | 2.61 | 2.95 |
| MDV3100 | 16.98 | 9.15 | 1.54 | 3.34 | 2.88 | 2.69 |
| AA | 20.15 | 7.62 | 1.47 | 2.97 | 2.45 | 2.69 |
Note: Cells were treated with listed compound (0.1 nmol/L-100 μmol/L) for 7 d and the GI50 values for the antiproliferative effects of the compounds were determined from dose response curves (by a nonlinear regression analysis using Graph Pad Prism). Data represents the results from six independent experiments for each cell line.